BOSTON—Extended-duration prophylactic therapy with letermovir (Prevymis, Merck) may reduce cytomegalovirus (CMV) reactivation in allogeneic hematopoietic stem cell transplant (HSCT) patients, according to a small study presented at the 2022 Hematology/Oncology Pharmacy Association annual conference.